Gsk Share Discussion Threads

[poikka] 28/10/2020 13:37

We locked-down on the same day as Germany and NZ. That's it from me on the subject.

[williamcooper104] 28/10/2020 13:35

It was the perfect storm - Boris too busy shagging and brexiting to bother paying attention If we'd locked down earlier we could have come out earlier/had less economic damage The public were reasonably mature until all the yes but/no but and Bernard Castle messing around Plus zero strategy - can't expect people to lock down again unless they have an idea of what the plan is

[essentialinvestor] 28/10/2020 13:22

Cabotegravir - an injection every two months is prohibitively expensive for most
healthcare systems and arguably considerably inconvenient for the treatment population -
when a one a day pill is widely available.

I've never understood the rational behind a regular injectable from a commercial standpoint in Hiv
as mentioned here previously.

A long acting pill taken by mouth, that's totally different and in phase 3 testing atm from memory.

[porsche1945] 28/10/2020 13:10

Yeah, we didnt come out of lockdown too early, U.K. was locked down FIVE weeks longer than germany which is why the economic damage in the U.K. has been so bad, worst hit of all the major economies, as usual. Brexit has been a huge factor, trashed currency and lack of investment since 2016...its a double whammy. UK doomed and everyone should have been using masks, simple to do, from day one as on continent. Plus the brits are fat and unhealthy flobs in a damp sxxt climate, perfect storm.

[poikka] 28/10/2020 12:39

"We locked down too late and came out too early

Now the economic damage is going to be much worse than if we had had one sharp and long lock down at the start."

Oh please, no matter what this government does, the result is down to Joe and Mary Public, who are mostly daft and irresponsible.

[poikka] 28/10/2020 12:37

Hardly a go-go stock. This should be operating in a growth environment, but results are more worthy of a utility.

Even net debt has barely changed, taking everything into account.

Having said that, I do believe that EW is doing the right things, and it's worth holding for a good, pretty reliable, yield.

[essentialinvestor] 28/10/2020 12:30

Pfizer have pushed back their COVID-19 phsse 3 read out in to November.

[suetballs] 28/10/2020 12:26

Well - we got a dividend which is a bonus these days!
Suet

[alphorn] 28/10/2020 12:23

#589. That sentence didn't say much! Looking for some indication on the timing, in 2021, any target date or further off? Likely to be disruptive so interested in how long.

[onehanded] 28/10/2020 12:21

interesting new today from small UK company DVRG today

Cork company Deepverge is testing a Covid-19 breath-test device which it hopes will go to market in the new year and ultimately become an affordable mainstream consumer product. The Irish Examiner reports Deepverge plans to test 5,000 of the devices over the next two months before production starts. The unit will will cost around €75 and uses artificial intelligence and nanochips to detect the presence of Covid-19. The company are currently running tests in a lab in Scotland and will then carry out field trials with frontline workers and factory workers in the UK. Deepverge hope to have the product on the market early in the new year.

[williamcooper104] 28/10/2020 12:16

As an island we could have gone for zero covid until a vaccine turned up It's worked elsewhere - Japan/New Zealand/Taiwan/and i think Australia We locked down too late and came out too early Now the economic damage is going to be much worse than if we had had one sharp and long lock down at the start And while we can all calculate the odds/risks of each of us dying from covid with a good degree of confidence - none of us know what the long term health impacts of long covid are - but suffice to say - at moment they don't look good

[daneswooddynamo] 28/10/2020 12:15

No mention anywhere... apart from in the comments from the chief exec

[spud] 28/10/2020 12:15

2020 guidance
At full-year 2019 results on 5 February 2020 we provided guidance
with respect to expected full-year 2020 Adjusted EPS, being a decline
in the range of -1% to -4% at CER. This guidance reflected our expectations
for growth in key new products, and the start of a two-year period
in which we would continue to increase investment in these products
and in our R&D pipeline, alongside implementation of our new programme
which will prepare the Group for separation.

Our 2020 guidance was set before the COVID-19 pandemic and did not
include any potential impact on our business from the pandemic. It
also excluded any impact in 2020 from further material divestments
beyond those previously announced.

The COVID-19 pandemic has impacted Group performance, particularly
in the Vaccines business, during the first nine months of 2020. During
the third quarter we have seen a recovery in vaccination rates, including
adult immunisation rates in the United States returning to prior
year levels in the last month of the quarter.

This improvement, coupled with strong commercial execution of key
growth products and disciplined cost control, mean we are on track
to deliver within our earnings guidance range, with 2020 Adjusted
EPS now expected to be at the lower end of the -1% to -4% range at
CER. Achieving this guidance is supported by the expectation of sustained
recovery of adult immunisation rates, particularly in Shingrix.

All expectations, guidance and targets regarding future performance
and dividend payments should be read together with 'Outlook, assumptions
and cautionary statements' on pages 63 and 64.

If exchange rates were to hold at the closing rates on 30 September 2020 ($1.28/GBP1,
EUR1.10/GBP1 and Yen 136/GBP1) for the rest of 2020, the estimated
impact on 2020 Sterling turnover growth would be negative at around
1% and if exchange gains or losses were recognised at the same level
as in 2019, the estimated negative impact on 2020 Sterling Adjusted
EPS growth would be around 2%.

spud

[essentialinvestor] 28/10/2020 12:14

Closed my small trade from earlier in the week, still holding a few.

[milehouse] 28/10/2020 12:13

Not to worry.

[alphorn] 28/10/2020 12:13

Relief that they were still okish.

No mention anywhere about the upcoming business split.

[milehouse] 28/10/2020 12:11

@Dr Biotech where are they? Don't seem to be on the website?

[dr biotech] 28/10/2020 12:05

Results look ok, lower end of guidance which is higher than some forecasts.

[thebutler] 28/10/2020 08:29

Covid isn't blasting the economy, it's how we're reacting to it which is causing the damage.

[poikka] 28/10/2020 08:17

"GSK does not expect to profit from COVID-19 vaccines DURING THE PANDEMIC PHASE (My caps), and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness, either through GSK internal investments or with external partners."

[spud] 28/10/2020 08:13

Sanofi, GSK to Supply 200 Million Doses of Covid-19 Vaccine to COVAX FacilitySource: Dow Jones News Sanofi SA and GlaxoSmithKline PLC signed a supply agreement with Gavi, the administrator of COVAX Facility, a mechanism for the procurement and distribution of Covid-19 vaccines, Sanofi said Wednesday.The French pharmaceutical company said the two drugmakers intend to supply 200 million doses of their adjuvanted recombinant protein-based Covid-19 vaccine to the COVAX Facility.spud

[tradermichael] 28/10/2020 08:12

2020 Third quarter
Released 28 October 2020
We will announce our third quarter 2020 results at 12:00 GMT, 08:00 EDT on Wednesday 28 October. ​

Following the announcement there will be a webcast hosted by Emma Walmsley, CEO, Iain Mackay, CFO, and Luke Miels, President, Global Pharmaceuticals, at 14:00 GMT, 10:00 EDT.

[tradermichael] 28/10/2020 07:56

Sharks vs Humans?

[action] 28/10/2020 07:30

I hope Glaxo find another way for vaccine rather than kill sharks.